HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Drug evaluation: tesetaxel--an oral semisynthetic taxane derivative.

Abstract
Daiichi Sankyo Co Ltd (formerly Daiichi Seiyaku Co Ltd) was developing the oral semisynthetic taxane derivative tesetaxel for the potential treatment of cancer, including colorectal and gastric cancer. However, despite early signs of promise, in November 2006 tesetaxel was removed from Daiichi's development pipeline for failure to show clear benefit over existing, currently marketed agents for cancer chemotherapy.
AuthorsMaria Roche, Helena Kyriakou, Michael Seiden
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 7 Issue 12 Pg. 1092-9 (Dec 2006) ISSN: 1472-4472 [Print] England
PMID17209527 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Taxoids
  • tesetaxel
Topics
  • Animals
  • Antineoplastic Agents, Phytogenic (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
  • Clinical Trials, Phase I as Topic
  • Contraindications
  • Drug Evaluation, Preclinical
  • Humans
  • Neoplasms (drug therapy)
  • Structure-Activity Relationship
  • Taxoids (adverse effects, pharmacokinetics, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: